Progress and controversies in the management of seminoma.
A series of controversies in the management of testicular seminoma were raised in this paper. Some of these issues have been discussed in more detail while others such as the optimal dose of radiation in stage II disease, and the management of residual masses post-chemotherapy are discussed in the consensus statement generated from the conference. It is important to consider these controversies in the context of the excellent outcome of current therapy. It is extremely unusual in the management of neoplastic disease to be attempting to refine therapy when the expected cure rate is 97% as it is in seminoma. It is only when our understanding of the disease process is so good, and our treatments so effective, that we can afford to direct investigative effort to minimizing the morbidity of our therapies.
Thomas
G
G
Department of Radiation Oncology Toronto-Bayview Regional Cancer Centre, Ontario, Canada.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D013736:Testicular Neoplasms / Q000473:pathology / Q000628:therapy*